Integrating single-cell TCR landscapes and structural fingerprints to advance leukemia immunotherapies

Active Grant Awarded

Award ID
R56CA304245
Recipient
Awarding agency
Obligated
$526,443

Award facts

Assistance listing
93.310 Trans-NIH Research Support
Completion date 20% complete
Funding agency
Office of the Director National Institutes of Health, Department of Health and Human Services
Place of performance
Houston, TX 77204, USA

Award details come from USAspending.gov.

About this award

The Department of Health and Human Services, National Institutes of Health, Office of the Director awarded the University of Houston System, doing business as University of Houston, $526,443 on September 9, 2026, under Trans-NIH Research Support (Assistance Listing 93.310) as Grant R56CA304245. The award funds the establishment of the first Leukemia Immune Micro-Environment Single-TCR (LIMESTONE) atlas, which targets the difficulty of identifying leukemia-specific T-cell receptors in acute myeloid leukemia. Paired variable alpha and beta sequences for individual TCR molecules will be recovered from the largest collected single-cell TCR sequencing dataset, and the project integrates sequencing, antigen, and TCR information to characterize the structure of functional TCR molecules. The period of performance runs from September 9, 2026 to September 8, 2027, with performance in Houston, Texas 77204. The total obligated amount is $526,443.

Description

Abstract
The leukemia immune micro-environment (LIME) presents significant challenges in identifying shared leukemia- associated antigens and leukemia-specific T-cell receptors (TCRS), contributing to the limited success of T- cell-based immunotherapies against leukemias, especially when compared to solid tumors. The acute myeloid leukemia (AML) paradox, where donor T cells elicit potent graft-versus-leukemia effects but the underlying leukemic antigens are not characterized, is a key challenge. Systematic discovery of the AML immunogenic landscape is hindered by the lack of comprehensive tools and datasets integrating sequencing, antigen, and TCR information. Current methodologies for TCR analysis, such as bulk and single-cell sequencing, provide only a fragmented view, as they fail to accurately pair the variable alpha (VΩ) and beta (VΕ) chains. These technical limitations result in a lack of comprehensive data on the complete structure of functional TCR molecules limiting our UN- derstanding of antigen-specific immune responses in LIME. In addition, attempts to predict TCR specificities often rely on simplistic VΕ-CDR3 sequence matching and clustering with reference anti-viral TCRS (e.g., vdjdb). This approach ignores many determinant features of TCR specificity, as defined by the structure of a full TCR molecule (i.e., paired VΩ/VΕ heterodimer with an antigen-interacting surface formed by 6 CDR loops). Conse- quently, meaningful relationships between TCR repertoires in AML LIME and effective anti-leukemia immunity remain elusive, limiting T-cell-based therapy development. Here, we propose to address these limitations by establishing the first leukemia immune micro-environment single-TCR (LIMESTONE) atlas. Paired VΩ/VΕ SE- quences for individual TCR molecules will be recovered from the largest collected dataset of single-cell TCR sequencing from AML samples, and used for 3D modeling and molecular fingerprinting of TCRS. This will enable TCR repertoire analysis of the LIME at a level that has not yet been achieved for any type of cancer. We propose to develop novel and quantitative methods and workflows to perform structure-based analysis of TCRS from AML patients, including a new structure-informed TCR inference model, an innovative TCR clustering metric, and a graph neural network (GNN) model for AI-driven prediction of TCR specificity and off-target toxicity for AML- targeting immunotherapies. All these methods will be supported by and validated with experimental data from TCR sequencing, immunopeptidomics, and T-cell functional assays. The outcomes of this project include three critical resources: (I) the first structural atlas of AML-associated TCRS, to aid the development of TCR-based immunotherapies; (II) a structural catalog of the antigenic landscape in AML for identifying novel immunogenic peptides crucial for vaccine development; and (III) a new computational framework integrating multi-omics data, molecular modeling, and AI-driven predictions to analyze TCR repertoires from cancer samples, enhancing the specificity and safety of TCR-based therapies. These tools will be first developed and validated in the context of AML samples, but will later be expanded to advance immunotherapy design for other leukemias.

Quick answers

Who received award R56CA304245?

R56CA304245 was awarded to University Of Houston System by National Cancer Institute (National Institutes of Health) on September 9, 2026.

How much is award R56CA304245 worth?

$526,443 has been obligated on R56CA304245.

Which agency awarded R56CA304245?

National Cancer Institute (National Institutes of Health) awarded R56CA304245, with funding from Office of the Director (National Institutes of Health).

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award